CN107281230B - Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension - Google Patents
Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension Download PDFInfo
- Publication number
- CN107281230B CN107281230B CN201710482267.2A CN201710482267A CN107281230B CN 107281230 B CN107281230 B CN 107281230B CN 201710482267 A CN201710482267 A CN 201710482267A CN 107281230 B CN107281230 B CN 107281230B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- leaf extract
- ethanol
- taxus media
- taxus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition, a preparation method thereof and application thereof in preparing a medicament for treating hypertension, wherein the pharmaceutical composition comprises taxus media leaf extract and a pharmaceutically acceptable carrier, wherein the weight percentage of the taxus media leaf extract is 0.1-99.9%. The pharmaceutical composition has good treatment effect on hypertension, simple preparation process and obvious drug effect, provides more choices for clinical treatment of hypertension, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese pharmacology, and relates to a pharmaceutical composition, a preparation method thereof and application thereof in preparing a medicine for treating hypertension.
Background
Hypertension (hypertension) is a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic pressure and/or diastolic pressure) (systolic pressure not less than 140 mm hg, diastolic pressure not less than 90 mm hg), which may be accompanied by functional or organic damage to organs such as heart, brain, kidney, etc. Hypertension is the most common chronic disease and also the most major risk factor for cardiovascular and cerebrovascular diseases.
Taxus chinensis var. mairei is also called as Taxus beauty, is a plant of Taxus genus of Taxus family of Taxaceae of Taxus order of Taxus class of Eugenia plant, is specially produced in China, is mainly distributed in Yangtze river basin, south mountain area, mountain areas of Henan, Shanxi (Qinling mountain), Gansu province and other mountainous regions or brook, and is a plant with fastest growth and widest distribution in Taxus genus.
Besides containing small molecular active substances such as paclitaxel and the like, the leaves of the taxus mairei also find that active flavone components contained in the leaves of the taxus mairei have antioxidant and antibacterial activities, but no report on treatment of hypertension by xanthone in the leaves exists at present.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a pharmaceutical composition, a preparation method thereof and application thereof in preparing a medicine for treating hypertension.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a pharmaceutical composition comprising a taxus media leaf extract and a pharmaceutically acceptable carrier, wherein the weight percentage of the taxus media leaf extract is 0.1-99.9%, such as 0.1%, 0.2%, 0.3%, 0.5%, 0.8%, 1%, 2%, 5%, 8%, 10%, 13%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98%, 99% or 99.9%.
Preferably, the taxus media leaf extract contains flavonoid components and does not contain taxane components.
In the invention, the taxus media leaf extract has a plurality of chemical components, is mainly rich in flavonoid components and almost has no taxane components, has the effect of compatibility use of the traditional Chinese medicine compound, and has small toxic and side effects compared with a single medicine when being used as a natural medicine. The Taxus media extract disclosed by the invention is found to have the effect of treating hypertension for the first time.
Preferably, the taxus media leaf extract is 1 to 90 wt%, preferably 20 to 85 wt%, and more preferably 40 to 80 wt%.
Preferably, the taxus media leaf extract is an alcohol extract and/or a traditional Chinese medicine extract.
Preferably, the pharmaceutically acceptable carrier is mannitol, sorbitol, sorbic acid, potassium sorbate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, vitamin A, vitamin C, vitamin E, vitamin D, azone, disodium EDTA, calcium sodium EDTA, carbonate of a monovalent alkali metal, acetate of a monovalent alkali metal, phosphate of a monovalent alkali metal, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, an amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, a silicon derivative, cellulose, a cellulose derivative, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, Tween 60-80, span-80, wax, lanolin, liquid paraffin, sodium chloride, sodium EDTA, calcium disodium EDTA, carbonate, phosphate of a monovalent alkali metal, sodium phosphate of a monovalent alkali metal, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, Cetyl alcohol, gallic acid esters, agar, triethanolamine, basic amino acid, urea, allantoin, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, beta-cyclodextrin, phospholipid material, kaolin, talcum powder, calcium stearate, magnesium stearate, vegetable oil, phospholipid, polyethylene glycol phospholipid derivative, oleic acid, oleate, antioxidant, or ionic complexing agent.
Preferably, the vegetable oil is any one or a mixture of at least two of soybean oil, medium-chain oil, olive oil, tea oil, palm oil, angelica oil, sea buckthorn oil, zedoary oil, ligusticum wallichii oil, coix seed oil, safflower oil, zanthoxylum oil and garlic oil.
Preferably, the phospholipid is one or a mixture of at least two of egg yolk lecithin, soybean phospholipid, hydrogenated egg yolk lecithin, hydrogenated soybean phospholipid and synthetic phospholipid.
Preferably, the polyethylene glycol phospholipid is any one or a mixture of at least two of polyethylene glycol-cephalin, polyethylene glycol-cholesterol, polyethylene glycol-di-fatty glyceride, polyethylene glycol-fatty acid ester, polyethylene glycol-fatty amine or polyethylene glycol-fatty alcohol.
Preferably, the antioxidant is vitamin E.
Preferably, the dosage form of the pharmaceutical composition is any one or a combination of at least two of tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, hard capsules, soft capsules, oral liquids, buccal agents, granules, medicinal granules, pills, powders, ointments, pellets, suspensions, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops or patches.
Preferably, the extraction method of the taxus media leaf extract is any one or a combination of at least two of an alcohol extraction method, a chromatography method, a vacuum extraction method, a supercritical fluid extraction method, an ultrasonic extraction method, an enzyme extraction method, a microwave extraction method, a charge extraction method and a semi-bionic extraction method, and preferably the alcohol extraction and chromatography are combined.
Preferably, the extraction method of the taxus media leaf extract comprises the following steps: coarsely pulverizing Taxus x media leaf, decocting with ethanol, cooling to room temperature, and recovering under reduced pressure to dry; performing macroporous resin column chromatography on the crude product of the extract, eluting with water to remove saccharide components, and eluting with ethanol; performing chromatographic separation on the ethanol elution concentrate by using a polyamide column, and performing elution by using elution gradients of water, 30% ethanol, 60% ethanol and 90% ethanol respectively. And (3) taking the 90% ethanol eluent, concentrating under reduced pressure, and drying in vacuum to obtain the taxus media leaf extract.
Preferably, when the alcohol is added for decoction, the weight ratio of the taxus media leaves to the alcohol is 1 (5-15), for example, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14 or 1:15, preferably 1 (9-12), and the extraction of the taxus media leaves by using too little alcohol is not beneficial to the extraction of the effective components, while the extraction of the effective components cannot be further obviously increased by using too much alcohol, but the extraction amount of other components is increased, so that the proportioning relation of the components in the extract is affected, and the action effect of the extract is affected.
Preferably, the number of times of decoction is 2-5, for example, 2, 3, 4 or 5, preferably 3.
Preferably, the time of each decoction is 1-3 hours, for example, 1 hour, 1.3 hours, 1.5 hours, 1.8 hours, 2 hours, 2.2 hours, 2.5 hours, 2.8 hours or 3 hours, preferably 2 hours, too short of decoction can prevent the active ingredients from being leached out and affect the effect of the extract, too long of decoction can destroy the active ingredients and can also affect the proportion relationship of the ingredients, so that the monarch, minister, assistant and guide coordination relationship among the ingredients in the extract is affected, and the treatment effect on hypertension is further affected.
Preferably, the alcohol in the alcohol decoction is any one of methanol, methanol water solution, ethanol or ethanol water solution or a mixture of at least two of methanol, ethanol, 80% methanol water solution or 70% ethanol water solution, and more preferably 70% ethanol water solution;
preferably, the elution volume of each elution gradient is 3 to 7 column volumes, e.g. may be 3 column volumes, 3.5 column volumes, 4 column volumes, 4.5 column volumes, 5 column volumes, 5.5 column volumes, 6 column volumes, 6.5 column volumes or 7 column volumes, preferably 5 column volumes.
Preferably, the vacuum drying temperature is 20-80 ℃, for example can be 20 ℃, 21 ℃, 22 ℃, 23 ℃, 25 ℃, 26 ℃, 28 ℃, 30 ℃, 35 ℃, 40 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 75 ℃ or 80 ℃, preferably 30-60 ℃, more preferably 50 ℃.
In a second aspect, the present invention provides a process for preparing a pharmaceutical composition according to the first aspect, the process comprising: mixing the taxus media leaf extract and a pharmaceutically acceptable carrier to enable the weight percentage of the taxus media leaf extract to be 0.1-99.9%, and obtaining the pharmaceutical composition.
In the present invention, the pharmaceutical composition may be prepared into corresponding dosage forms through formulation processes known in the art.
In a third aspect, the present invention provides a use of the pharmaceutical composition according to the first aspect in the preparation of a medicament for treating hypertension.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention utilizes the taxus media leaf extract to be matched with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition, and has good treatment effect on hypertension.
(2) Compared with extracts of other parts of the taxus media, the extracted taxus media leaf extract has a specific effect of treating hypertension, and through a specific extraction process, effective components and other auxiliary components in the extract have a better matching relation, so that the monarch, minister, assistant and guide matching relation among the components is well played, and a good treatment effect on the hypertension is achieved.
(3) The medicine provided by the invention has the advantages of simple preparation process and obvious drug effect, provides more choices for clinical treatment of hypertension, and has wide application prospects.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1
In this example, a pharmaceutical composition was prepared by the following method:
(1) extraction of taxus media extract
Taking 500g of Taxus media leaf coarse powder, decocting with 10 times of 70% ethanol for 1h each time for 3 times. After decocting, cooling to room temperature, and recovering under reduced pressure to dryness. And (3) performing macroporous resin column chromatography on the crude extract, eluting with 5 times of column volume of water to remove saccharide components, and eluting with 5 times of column volume of ethanol. Separating the ethanol eluate concentrate with polyamide column chromatography, and eluting with water, 30% ethanol, 60% ethanol, and 90% ethanol, wherein the elution volume of each gradient is 5 times of the column volume. Collecting 90% ethanol eluate, concentrating under reduced pressure, and vacuum drying at 50 deg.C to obtain Taxus media leaf extract.
(2) Mixing the extracted taxus media leaf extract with polyethylene glycol to enable the weight percentage of the taxus media leaf extract to be 60%, and then preparing the taxus media leaf extract into a capsule medicine to obtain the medicine composition.
Example 2
In this example, a pharmaceutical composition was prepared by the following method:
(1) extraction of taxus media extract
Taking 500g Taxus x media leaf coarse powder, adding 15 times of 80% methanol for decocting for 1h for 3 times, cooling to room temperature, and recovering under reduced pressure to dry. And (3) performing macroporous resin column chromatography on the crude extract, eluting with 5 times of column volume of water to remove saccharide components, and eluting with 5 times of column volume of ethanol. Separating the ethanol eluate concentrate with polyamide column chromatography, and eluting with water, 30% ethanol, 60% ethanol, and 90% ethanol, wherein the elution volume of each gradient is 7 times of the column volume. Collecting 90% ethanol eluate, concentrating under reduced pressure, and vacuum drying at 50 deg.C to obtain Taxus media leaf extract.
(2) Mixing the extracted taxus media leaf extract with sorbitol to enable the weight percentage of the taxus media leaf extract to be 80%, and then preparing the taxus media leaf extract into a capsule medicine to obtain the medicine composition.
Example 3
In this example, a pharmaceutical composition was prepared by the following method:
(1) extraction of taxus media extract
Taking 500g Taxus x media leaf coarse powder, decocting with 5 times of 70% ethanol for 2 times each time for 2h, cooling to room temperature, and recovering under reduced pressure to dry. And (3) performing macroporous resin column chromatography on the crude extract, eluting with 5 times of column volume of water to remove saccharide components, and eluting with 5 times of column volume of ethanol. Separating the ethanol eluate concentrate with polyamide column chromatography, and eluting with water, 30% ethanol, 60% ethanol, and 90% ethanol, wherein the elution volume of each gradient is 3 times of the column volume. Collecting 90% ethanol eluate, concentrating under reduced pressure, and vacuum drying at 50 deg.C to obtain Taxus media leaf extract.
(2) Mixing the extracted taxus media leaf extract with mannitol to enable the weight percentage of the taxus media leaf extract to be 90%, and then preparing the taxus media leaf extract into a capsule medicine to obtain the medicine composition.
Example 4
In this example, a pharmaceutical composition was prepared by the following method:
(1) extraction of taxus media extract
Taking 500g Taxus x media leaf coarse powder, decocting with 8 times of 70% ethanol for 3 times each time for 3h, cooling to room temperature, and recovering under reduced pressure to dry. And (3) performing macroporous resin column chromatography on the crude extract, eluting with 5 times of column volume of water to remove saccharide components, and eluting with 5 times of column volume of ethanol. Separating the ethanol eluate concentrate with polyamide column chromatography, and eluting with water, 30% ethanol, 60% ethanol, and 90% ethanol, wherein the elution volume of each gradient is 6 times of the column volume. Collecting 90% ethanol eluate, concentrating under reduced pressure, and vacuum drying at 50 deg.C to obtain Taxus media leaf extract.
(2) Mixing the extracted taxus media leaf extract with polyethylene glycol phospholipid to ensure that the weight percentage of the taxus media leaf extract is 20%, and then preparing the taxus media leaf extract into a capsule medicine to obtain the pharmaceutical composition.
Example 5
In this example, the antihypertensive activity of the pharmaceutical composition of example 1 of the present invention was verified by the following method:
before the formal start of the experiment, the rats are normally raised for one week and then divided into two parts, wherein the first part randomly divides 60 rats into 6 groups of 10 rats. A blank control group, a model control group, and a captopril positive control group (0.005 g/kg. d)-1) And the high-dose group (4 g/kg. d) of the yew leaf extract-1) And the dosage group in the yew leaf extract (2 g/kg. d)-1) The low dose group of the yew leaf extract (1 g/kg. d)-1). The rats were gavaged according to body weight with a gavage volume of 1ml/100g, a blank group with 1.5% sodium carboxymethylcellulose solution, a model group with 10% fructose solution, and the other groups with the corresponding drug and 10% fructose solution, continuously gavage for 4 weeks, and measuring rat tail arterial blood pressure every week.
TABLE 1 Effect of high, Medium and Low dose extracts on rat tail arterial blood pressure (X + -SD, unit mmHg)
aRepresentative vs. blank, P<0.05；bComparison of the representation with the model set, P<0.05。
The results in table 1 show that the blood pressure of the rats in the blank group was significantly different from that in the model group (P <0.05) from week 2, indicating successful modeling. By week 2, rats given high and medium doses exhibited a drop in blood pressure that tended to be significantly different (P <0.05) from that of the model group. Therefore, the taxus chinensis leaf extract composition with high and medium dose can effectively reduce the hypertension of rats.
The above-mentioned tests on the hypotensive activity of the compositions prepared in examples 2 to 4 showed that the pharmaceutical composition of the Taxus chinensis leaf extract was effective in reducing hypertension in rats at high and medium doses.
In conclusion, the taxus chinensis leaf extract disclosed by the invention is used as a natural medicine, can be used for remarkably improving and reducing blood pressure, provides more choices for clinical treatment of hypertension, and has a wide application prospect.
The applicant states that the pharmaceutical composition, the preparation method and the application thereof are illustrated by the above examples, but the invention is not limited to the above examples, i.e. the invention is not limited to the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Claims (18)
1. A pharmaceutical composition with hypertension treatment effect is characterized by comprising taxus media leaf extract and a pharmaceutically acceptable carrier, wherein the weight percentage of the taxus media leaf extract is 0.1-99.9%;
the extraction method of the taxus media leaf extract is a combination of alcohol extraction and chromatography, and specifically comprises the following steps:
coarsely pulverizing Taxus x media leaf, decocting with 80% methanol water solution or 70% ethanol water solution, cooling to room temperature, and recovering under reduced pressure to dry; performing macroporous resin column chromatography on the crude product of the extract, eluting with water to remove saccharide components, and eluting with ethanol; performing chromatographic separation on the ethanol elution concentrate by using a polyamide column, and performing elution by using elution gradients of water, 30% ethanol, 60% ethanol and 90% ethanol respectively; and (3) taking the 90% ethanol eluent, concentrating under reduced pressure, and drying in vacuum to obtain the taxus media leaf extract.
2. The pharmaceutical composition of claim 1, wherein the taxus media leaf extract contains flavonoids and no taxanes.
3. The pharmaceutical composition of claim 1, wherein the taxus media leaf extract is present in an amount of 1-90% by weight.
4. The pharmaceutical composition of claim 1, wherein the taxus media leaf extract is present in an amount of 20-85% by weight.
5. The pharmaceutical composition of claim 1, wherein the taxus media leaf extract is present in an amount of 40-80% by weight.
6. The pharmaceutical composition of claim 1, wherein the weight ratio of Taxus media leaf to alcohol is 1 (5-15) during the decoction.
7. The pharmaceutical composition of claim 1, wherein the weight ratio of Taxus media leaf to alcohol is 1 (9-12) during the decoction.
8. The pharmaceutical composition of claim 1, wherein the number of said decocting is 2-5.
9. The pharmaceutical composition of claim 1, wherein the number of said decocting is 3.
10. The pharmaceutical composition of claim 9, wherein the time for each decoction is 1-3 hours.
11. The pharmaceutical composition of claim 1, wherein the solution used for decoction is 70% aqueous ethanol.
12. The pharmaceutical composition of claim 1, wherein the elution volume of each elution gradient is 3-7 column volumes.
13. The pharmaceutical composition of claim 1, wherein the elution volume of each elution gradient is 5 column volumes.
14. The pharmaceutical composition of claim 1, wherein the vacuum drying temperature is 20-80 ℃.
15. The pharmaceutical composition of claim 1, wherein the vacuum drying temperature is 30-60 ℃.
16. The pharmaceutical composition of claim 1, wherein the vacuum drying temperature is 50 ℃.
17. A process for the preparation of a pharmaceutical composition according to any one of claims 1 to 16, wherein the process comprises: mixing the taxus media leaf extract and a pharmaceutically acceptable carrier to enable the weight percentage of the taxus media leaf extract to be 0.1-99.9%, and obtaining the pharmaceutical composition.
18. Use of a pharmaceutical composition according to any one of claims 1-17 for the manufacture of a medicament for the treatment of hypertension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710482267.2A CN107281230B (en) | 2017-06-22 | 2017-06-22 | Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710482267.2A CN107281230B (en) | 2017-06-22 | 2017-06-22 | Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107281230A CN107281230A (en) | 2017-10-24 |
| CN107281230B true CN107281230B (en) | 2021-06-11 |
Family
ID=60097528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710482267.2A Active CN107281230B (en) | 2017-06-22 | 2017-06-22 | Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281230B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213174A (en) * | 2017-06-22 | 2017-09-29 | 江苏红豆杉药业有限公司 | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing preventing and treating nerve degenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244991B (en) * | 2008-03-21 | 2011-05-18 | 昆明万宝集源生物科技有限公司 | Method for extracting and purifying sequoyitol by using solvent deposition |
| CN103099826B (en) * | 2012-12-31 | 2015-02-04 | 宁波泰康红豆杉生物工程有限公司 | Method for extracting taxusflavone from taxus chinensis leaves |
| CN104248649B (en) * | 2014-09-24 | 2017-08-18 | 江苏红豆杉药业有限公司 | A kind of preparation method and applications of Chinese yew extract |
| CN107213174A (en) * | 2017-06-22 | 2017-09-29 | 江苏红豆杉药业有限公司 | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing preventing and treating nerve degenerative diseases |
| CN107137434B (en) * | 2017-06-22 | 2021-04-30 | 无锡紫杉药业有限公司 | Pharmaceutical composition, preparation method thereof and application thereof in preparation of coxsackie virus resistant medicine |
-
2017
- 2017-06-22 CN CN201710482267.2A patent/CN107281230B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107281230A (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
| CN105983015B (en) | A pharmaceutical composition containing silibinin and VE | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN106176837B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN107137434B (en) | Pharmaceutical composition, preparation method thereof and application thereof in preparation of coxsackie virus resistant medicine | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN114524825A (en) | Artemisia sphaerocephala lactone A-T, pharmaceutical composition thereof, and preparation method and application thereof | |
| CN107281230B (en) | Pharmaceutical composition, preparation method thereof and application thereof in preparation of medicine for treating hypertension | |
| CN103271978B (en) | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness | |
| CN101134057B (en) | Compound medicament of natural plant extract containing paclitaxel and anticancer application thereof | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102133220A (en) | Preparation method of pulsatilla saponin matter as well as preparation method of preparation thereof and application of pulsatilla saponin matter in preparing medicaments for treating cancers | |
| CN1679704A (en) | Medicinal preparation containing notoginseng and seabuckthorn fruit for cardio-cerebral blood vessel diseases and its preparing method | |
| WO2017113476A1 (en) | Traditional chinese medicine composition for treating gastritis | |
| CN102225095B (en) | Effective fraction of plantain seeds as well as preparation method and application thereof | |
| JPS6025933A (en) | Agent for mitigating symptoms of cancer | |
| CN114796280A (en) | Compound paracetamol and chlorphenamine maleate granules and preparation process thereof | |
| CN102670865A (en) | Process for extracting active ingredients of American eleutherine rhizome | |
| CN101766676B (en) | Extract of Albizia chinensis (Osbeck) Merr, preparation method, combination and purpose thereof | |
| CN101745016B (en) | Extraction method of 'ginseng/radix ophiopogonis and schisandra chinensis' and preparation thereof | |
| CN101745017B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN110201014A (en) | A kind of preparation method and applications of Panax stipuleanatus Tsai et Feng total saposins | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN107213174A (en) | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing preventing and treating nerve degenerative diseases | |
| CN103223058B (en) | Fructus Viticis Negundo total flavone extract, and preparation method and medicinal uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.111, Qinxin Road, Donggang Town, Xishan District, Wuxi City, Jiangsu Province Applicant after: Wuxi Yeshan Pharmaceutical Co.,Ltd. Address before: 214199 red bean Industrial Park, Donggang Town, Xishan District, Jiangsu, Wuxi Applicant before: JIANGSU YEW PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 111 Qinxin Road, Donggang Town, Xishan District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi yew Pharmaceutical Co.,Ltd. Address before: 111 Qinxin Road, Donggang Town, Xishan District, Wuxi City, Jiangsu Province, 214000 Patentee before: Wuxi Yeshan Pharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |